Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 4/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | TACR2 | P21452 | 7/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3942151 | 0.89 | PSEN1 (0.36) | TACR2 | |
| SCHEMBL7130715 | 0.85 | ALDH1A1 (0.36) | ALDH1A1TSHRL3MBTL1C5AR1GPR119 | |
| SCHEMBL2642053 | 0.82 | GAA (0.35) | ALDH1A1TSHRL3MBTL1C5AR1TACR2 | |
| SCHEMBL2642049 | 0.82 | GAA (0.35) | ALDH1A1TSHRL3MBTL1C5AR1TACR2 | |
| SCHEMBL2642542 | 0.77 | SLC6A3 (0.37) | ALDH1A1C5AR1GPR119 | |
| SCHEMBL14145928 | 0.70 | APP (0.31) | — | |
| SCHEMBL2642020 | 0.70 | NPY5R (0.34) | TACR2 | |
| SCHEMBL2642173 | 0.70 | NPY5R (0.34) | TACR2 | |
| SCHEMBL1858505 | 0.70 | GAA (0.39) | ALDH1A1 | |
| SCHEMBL2644230 | 0.70 | GAA (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY LEA (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | ALDH1A1 3003/4885TSHR 2604/4885L3MBTL1 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.